Bimatoprost is used to lower the elevated intraocular pressure in adults. So, any incidences of high pressure inside your eye may be treated by this drug. An increase in intraocular pressure occurs, for example, when the eye fluid channel is blocked or misplaced.
394 Item Items
Warning: Last items in stock!
Product name - Generic Latisse - Bimatoprost
Qualitative and quantitative composition - The chemical formula of the drug is C25H37NO4. It is used as an eye drop (colorless) and available in the market as 0.3mg/ml and 0.1mg/ml concentrations, which is equivalent to 0.6mg and 0.2mg benzalkonium chloride respectively.
Action mechanism - Generic Latisse (Bimatoprost) as an F2α structural analog similar to tafluprost and travoprost. However, it has no action on the F receptor of prostaglandin or any other recognized receptors of prostaglandin, as opposed to these drugs. It improves the eye's aqueous fluid outflow and reduces the intraocular pressure. Bimatoprost is believed to mimic the prostamides (has chemical similarity) in the human. Prostamides is linked to prostaglandin, but its action mechanism is not known. There has so far been no identification of prostamide receptor. Bimatoprost may function by uveoscleral routes and through the trabecular meshwork.
Indication - Generic Latisse (Bimatoprost) is indicated only to adults as an ophthalmic solution (0.03% or 0.01%) to reduce Intraocular pressure and to increase the length of the eyelashes making eyelashes longer and thicker.
Mode of administration - For cosmetic use to increase the length of the eyelash the Generic Latisse solution is applied with an applicator on the base of eyelashes evenly (on the skin). If swallowed, this cosmetic product can be hazardous.
Contraindication - Bimatoprost should not be used during pregnancy and lactation. It is also not indicated to infants and children. Please note that the contraindications may vary depending on the formulation of the drug. Bimatoprost should only be used after careful consideration by a physician. It is not given to patients with macular edema, viral infection in the eye, iris inflammation, impaired respiratory and kidney function, and slow pulse or low blood pressure.
The drug should be discontinued or not prescribed if any previous history of adverse effects is found against benzalkonium chloride.
Special cautions and warnings - Sometimes medicinal substances trigger allergic reactions. If you experience any signs of an allergic reaction, tell your doctor or pharmacist immediately. Do not let the medicine to come in direct contact with the skin in any part of the body as it may trigger irritation and inflammation. If you have overdosed this medicine and have severe symptoms like breathing difficulty or fainting, seek immediate medical attention. It is harmful to swallow this drug.
Never try to increase doses without intimating your physician. If you missed any dose, do not try to compensate it by taking an additional dose. Skip the missed dose and continue having the doses as prescribed from the next dose.
Sometimes the drug causes a permanent increase in iris pigmentation. When only one eye is treated this may result in differences in appearance between the two eyes of the same person.
Product interaction - Please note that the interactions may vary depending on the drug formulation. If the active ingredient is used together with other similar substances (such as latanoprost, travoprost ) on the eye, the effect on intraocular pressure may be reduced. Otherwise, no further interactions are known.
Side effects - The side effects depend on the concentration of the active substance. Common latisse generic side effects include itchiness in the eyes, eyelash growth, pain in the eye, redness of the eyelid, eye irritation, darkening of the skin, hair growth, and corneal inflammation.
Other side effects may also be seen such as swelling of the conjunctiva, nausea, iris discoloration, eyelid swelling, eyelid encrustation, dry skin, conjunctivitis, blurred vision, etc.
Several rare side effects can be seen in some individuals that may include water retention in the retina (macular edema), ocular allergy, dry eyes, darkening of the iris and eyelids, asthma and respiratory problems, and allergic dermatitis.
Interesting facts -
Each ml contains :
Bimatoprost 0.3 mg
Benzalkonium Chloride IP 0.005% w/v
Sterile aqueous vehicle q.s.
Mechanism of Action:
Bimatoprost is a prostamide, a synthetic structural analog of prostaglandin with ocular hypotensive activity. It selectively mimics the effects of naturally occurring substances, prostamides. Bimatoprost is believed to lower intraocular pressure (IOP) in humans by increasing outflow of aqueous humor through both the trabecular meshwork and uveoscleral routes. Elevated IOP presents a major risk factor for glaucomatous field loss. The higher the level of IOP, the greater the likelihood of optic nerve damage and visual field loss.
There was no significant systemic drug accumulation over time.
INDICATIONS AND USAGE
Generic Latisse / Bimat 0.03% is indicated for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension who are intolerant of other intraocular pressure lowering medications or insufficiently responsive (failed to achieve target IOP determined after multiple measurements over time) to another intraocular pressure lowering medication.
Bimatoprost is contraindicated in patients with hypersensitivity to Bimatoprost or any other ingredient in this product.
Generic Latisse / Bimatoprost has been reported to cause changes to pigmented tissues. These reports include increased pigmentation and growth of eyelashes and increased pigmentation of the iris and periorbital tissue (eyelid). These changes may be permanent.
Patients may slowly develop increased brown pigmentation of the iris. This change may not be noticeable for several months to years. Typically the brown pigmentation around the pupil is expected to spread concentrically towards the periphery in affected eyes, but the entire iris or parts of it may also become more brownish. Until more information about increased brown pigmentation is available, patients should be examined regularly and, depending on the clinical situation, treatment may be stopped if increased pigmentation ensues. The increase in brown iris pigment is not expected to progress further upon discontinuation of treatment, but the resultant color change may be permanent.
Neither nevi nor freckles of the iris are expected to be affected by treatment.
Bimatoprost should be used with caution in patients with active intraocular inflammation (e.g., uveitis).
Macular edema, including cystoid macular edema, has been reported during treatment with bimatoprost ophthalmic solution. Bimatoprost should be used with caution in aphakic patients, in pseudophakic patients with macular edema.
Bimatoprost has not been evaluated for the treatment of angle closure, inflammatory or neovascular glaucoma. Bimatoprost should not be administered while wearing contact lenses.
Teratogenic Effects: Pregnancy Category C.
There are no adequate and well-controlled studies of Bimatoprost administration in pregnant women. Because animal reproductive studies are not always predictive of human response, Bimatoprost should be administered during pregnancy only if the potential benefit justifies the potential risk to the fetus.
It is not known whether Generic Latisse / Bimatoprost is excreted in human milk, although in animal studies, Bimatoprost has been shown to be excreted in breast milk. Because many drugs are excreted in human milk, caution should be exercised when Bimatoprost is administered to a nursing woman.
Safety and effectiveness in pediatric patients have not been established.
No overall clinical differences in safety or effectiveness have been observed between elderly and other adult patients.
In clinical trials, the most frequent events associated with the use of Bimatoprost occurring in approximately 15% to 45% of patients, in descending order of incidence, included conjunctival hyperemia, growth of eyelashes, and ocular pruritus.
DOSAGE AND ADMINISTRATION
The recommended dosage is one drop in the affected eye(s) once daily in the evening. The dosage of Bimatoprost should not exceed once daily since it has been shown that more frequent administration may decrease the intraocular pressure lowering effect.
Reduction of the intraocular pressure starts approximately 4 hours after the first administration with maximum effect reached within approximately 8 to 12 hours.
Bimatoprost may be used concomitantly with other topical ophthalmic drug products to lower intraocular pressure. If more than one topical ophthalmic drug is being used, the drugs should be administered at least five minutes apart.
Available in 3 ml vial.
Store below 25°C.
Manufactured in India by :
ajanta pharma limited
Ajanta House, Charkop,
Kandivli (W), Mumbai 400 067.